Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Text search

Sort by Random

Display 30 Products per page

Schizophrenia and Bipolar Disorder KOL Interview – US, East Coast

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, long-acting injectables, late-phase pipeline therapies, and unmet needs for schizophrenia and bipolar disorder. Key pipeline assets highlighted include Lybalvi (ALKS 3831), MIN-101, Nuplazid, Caplyta, BXCL501, and six-monthly paliperidone depot injection.
April 28, 2021
Find out more
Ocaliva
Read More
Ocaliva (obeticholic acid; Intercept Pharmaceuticals) is a selective farnesoid X receptor (FXR) agonist. FXR is a nuclear bile acid receptor involved in the regulation of bile acids, lipids, and possibly glucose. Ocaliva is a derivative of chenodeoxycholic acid, the endogenous FXR agonist found naturally in human bile acid. By activating FXR, Ocaliva improves insulin sensitivity and inhibits lipogenesis, which reduces fat buildup in the liver and results in decreased inflammation. Ocaliva has also been linked to weight loss. Ocaliva is currently approved in the US and EU for primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.
July 22, 2019
Find out more
Inbrija
Read More
Inbrija (Acorda Therapeutics) is an inhaled formulation of levodopa, in development as an adjunct to existing oral levodopa formulations in patients experiencing motor fluctuations.
June 21, 2018
Find out more
Aubagio
Read More
Aubagio is the major active metabolite of Arava (leflunomide), Sanofi’s oral treatment for rheumatoid arthritis, and is a dihydroorotate dehydrogenase (DHODH) inhibitor.
November 24, 2017
Find out more
Market Spotlight: Sickle Cell Anemia

$1,318.00

This Market Spotlight report covers the Sickle Cell Anemia market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals.
August 25, 2022
Find out more
Cimzia
Read More
Cimzia (certolizumab; UCB/Astellas [also marketed by Dermira in some approved indications]) is a PEGylated humanized monoclonal antibody fragment, with high affinity for both soluble and membrane-bound tumor necrosis factor alpha.
July 31, 2018
Find out more
Biomedtracker Q3 2017 Outlook Report

$599.00

In this report, we cover catalysts from 21 drugs expected to occur in Q3 2017. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided.
August 2, 2017
Find out more
Neuromodulation: Deep Brain Stimulation and Vagus Nerve Stimulation Devices Market

$4,750.00

This report provides an overview of primary neurological diseases/disorders treated with deep brain stimulation (DBS) and vagus nerve stimulation (VNS), as well as overviews of DBS and VNS neuromodulation technologies, competitors, sales, forecasts, and competitive and market analysis. Markets covered by this analysis comprise the US, Japan, the five major European markets (France, Germany, Italy, Spain, and the UK), and the Rest of World (RoW) markets.
May 26, 2022
Find out more
Market Spotlight: Hypogonadism

$1,318.00

The approved drugs in the hypogonadism space target androgen receptors, estrogen receptor alpha, and estrogen receptor beta. These are commonly administered via the transdermal route, with a smaller number of products being available in oral, intramuscular, intranasal, sublingual/oral transmucosal, subcutaneous, and topical formulations.
November 18, 2022
Find out more
Datamonitor Healthcare Meningococcal and Pneumococcal Vaccines KOL Interview – US

$599.00

An interview with a US key opinion leader (KOL) on meningococcal and pneumococcal vaccination coverage rates, vaccination rate trends in main risk groups, key marketed vaccines, pipeline approaches, and addressing unmet needs.
November 9, 2018
Find out more
Treanda/Bendeka
Read More
Treanda (bendamustine; Teva/Mundipharma/Eisai) is an intravenous cytotoxic agent.
January 31, 2019
Find out more
Prostate Cancer Diagnostics and Minimally Invasive Treatments Market

$4,750.00

This comprehensive medical market and technology report provides an overview and in-depth market analysis of selected next-generation prostate cancer diagnostics, biopsy, and minimally invasive treatments.
May 4, 2022
Find out more
Breast Cancer Pulse Survey

$599.00

Drugs and drug candidates discussed:

palbociclib, neratinib, Herceptin, Perjeta, Kadcyla, Tykerb, Afinitor
April 23, 2014
Find out more
United States, Cardiovascular Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure Volumes

$1,995.00

This report presents the prevalence and number of hospital discharges in the UnitedStates (U.S.) as well as the surgical procedure volumes for selected cardiovascular/thoracic diseases/disorders.
January 1, 2013
Find out more
Cardiac Ablation Catheters Market

$4,750.00

Cardiac rhythm disorders (also referred to as arrhythmias or dysrhythmias) involve malfunctions of the heart’s electrical system, and may be congenital (present at birth) or acquired (developing after birth).
May 6, 2021
Find out more
Head and Neck Cancer KOL Interview – US, Southeast

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for head and neck cancer. Disease stratification by staging and origin of the primary tumor, as well as unmet needs, are also discussed. Key pipeline assets highlighted include Imfinzi, Bavencio, tremelimumab, and Tecentriq.
April 14, 2020
Find out more
Surgical Heart Valve Management Products

$4,750.00

This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the surgical heart valve repair (annuloplasty) systems, surgical heart valve replacement products, and percutaneous balloon valvuloplasty (PBV) systems markets.
May 16, 2019
Find out more
Descovy
Read More
Descovy ([emtricitabine + tenofovir alafenamide (TAF)]; Gilead/Japan Tobacco) is a fixed-dose combination of two of Gilead’s nucleos(t)ide reverse transcriptase inhibitors, Emtriva (emtricitabine) and Vemlidy (tenofovir alafenamide [TAF]). The combination is currently approved in the US, Japan, and EU.
July 28, 2019
Find out more
Tarceva
Read More
Tarceva (erlotinib; Roche/Chugai/Astellas) is an orally available epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.
August 30, 2018
Find out more
Idalopirdine
Read More
Idalopirdine (Lundbeck/Otsuka) is an active, potent, and selective oral 5-hydroxytryptamine-6 receptor antagonist.
September 2, 2016
Find out more
Aurora-GT
Read More
United Therapeutics is developing a gene therapy product called Aurora-GT (endothelial nitric oxide-synthase-enhanced endothelial progenitor cells)
October 29, 2018
Find out more
Market Spotlight: Hodgkin’s Lymphoma

$1,318.00

This Market Spotlight report covers the Hodgkin’s Lymphoma market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, recent events and analyst opinion, a 10-year disease incidence and prevalence forecast, probability of success, and licensing and asset acquisition deals, as well as presenting drug-specific revenue forecasts.
November 7, 2022
Find out more
Disease Analysis: Migraine
Read More
Migraine is a common, disabling, and recurring neurological disorder characterized by severe headache co-occurring with nausea, vomiting, and other symptoms, the duration of which can range from hours to days.
November 2, 2022
Find out more
Innovation in Deal-Making

$3,000.00

In order to continually and effectively compete with its peers, as well as with smaller specialty pharmaceutical companies and biotechnology companies, the top 20 global pharmaceutical peer set turns to deal-making as a means to balance out its internally developed portfolio, and to take advantage of the broader capabilities of partners or takeover targets.
June 13, 2018
Find out more
Market Spotlight: Mantle Cell Lymphoma

$1,318.00

This Market Spotlight report covers the Mantle Cell Lymphoma (MCL) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
August 25, 2022
Find out more
Retinal Disorders (AMD and DME) Pulse

$599.00

We performed a 5-question survey of 20 ophthalmologists who treat retinal diseases to gauge current usage and projected future usage of agents for the treatment of wet and dry age-related macular degeneration (AMD) and diabetic macular edema (DME).
October 27, 2014
Find out more
Tecfidera
Read More
In May 2006, Biogen acquired Fumapharm and its pipeline multiple sclerosis (MS) drug dimethyl fumarate, coining it first BG-12 and later Tecfidera.
November 24, 2017
Find out more
Minimally Invasive Weight Loss (Bariatric) Devices Market

$4,750.00

The minimally invasive weight loss devices market (which includes laparoscopic adjustable gastric banding systems, intragastric balloon systems and implantable neuroregulators/gastric stimulation devices) was valued at more than $137m in 2016 and is expected to grow at a double-digit rate over the next 5 years. The overall market will be driven by highly favorable demographics, low penetration, strong demand for safe and effective nonsurgical weight loss therapies (filling an underserved market between weight loss drugs and drastic bariatric surgery) and increased adoption of novel, proprietary next-generation implantable weight loss technologies–particularly new/improved capsule-based intragastric balloon systems.
July 28, 2017
Find out more
Biopsy Devices Market

$4,750.00

Symptomatic benign prostatic hyperplasia (BPH) and prostatitis affect more than 100 million men worldwide, lowering quality of life with painful symptoms that can be difficult to manage.
May 2, 2017
Find out more
Praluent
Read More
Praluent (alirocumab; Sanofi/Regeneron) is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PSCK9) and is intended for the treatment of hypercholesterolemia.
November 20, 2019
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *